What comes after Ozempic
GLP-3 /Retatrutide
Target three of your body’s receptors.
GLP-1 regulates appetite and insulin.
GIP supports glucose handling.
Glucagon signals the body to use stored energy (fat).
Clinical data demonstrates advancements in weight management, liver function, and cardiovascular health.
In third-stage clinical trials.
Weight loss. Metabolic health. Liver function. Cardiovascular
At least 10% lower
prices by
A promise that goes further,
the more of us there are.
What you should know.
How can you sell a peptide that's still in clinical trials?
Peptides are simple molecules — chains of amino acids. Retatrutide has been in human trials since 2019, is currently in Phase 3, and FDA approval is anticipated in 2027. Catalyst sells the research-use-only version of the compound: a legal category distinct from the branded prescription drug Eli Lilly is bringing to market. No dosing guidance, no medical claims.
Why are peptides available without a prescription?
Peptides labeled for research use are not prescription drugs. They sit in a separate regulatory category, so the prescription requirement does not apply. Catalyst operates within the research-use-only (RUO) framework.
What does “Research Use Only” mean?
“Research Use Only” (RUO) is a regulatory designation under 21 CFR 809.10(c)(2). It applies to compounds manufactured and sold for non-clinical research, separate from drugs intended for diagnosis, treatment, or prevention of disease.
Is this a substitute for medical advice?
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. The content on Science Explained, the lab reports, and the third-party COAs is education about published research, not medical guidance.